These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 28440988)

  • 1. [How safe is the recombinant human growth hormone?].
    Calzada-León R
    Rev Med Inst Mex Seguro Soc; 2017; 55(3):341-352. PubMed ID: 28440988
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety of recombinant human growth hormone in treating children with growth hormone deficiency and idiopathic short stature.
    Chang S; Hui P
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2011 Apr; 33(2):123-6. PubMed ID: 21529437
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety of growth hormone treatment of children with idiopathic short stature: the US experience.
    Allen DB
    Horm Res Paediatr; 2011; 76 Suppl 3():45-7. PubMed ID: 21912165
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term safety of recombinant human growth hormone in turner syndrome.
    Bolar K; Hoffman AR; Maneatis T; Lippe B
    J Clin Endocrinol Metab; 2008 Feb; 93(2):344-51. PubMed ID: 18000090
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of growth hormone therapy in childhood.
    Bowlby DA; Rapaport R
    Pediatr Endocrinol Rev; 2004 Nov; 2 Suppl 1():68-77. PubMed ID: 16456485
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Benefits and risks of growth hormone in adults with growth hormone deficiency].
    Díez JJ; Cordido F
    Med Clin (Barc); 2014 Oct; 143(8):354-9. PubMed ID: 24485161
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Attach great importance to the standardized clinical usage and safety monitoring of recombinant human growth hormone in children].
    Liang Y; Luo XP
    Zhonghua Er Ke Za Zhi; 2013 Jun; 51(6):401-5. PubMed ID: 24120053
    [No Abstract]   [Full Text] [Related]  

  • 8. Headache, idiopathic intracranial hypertension and slipped capital femoral epiphysis during growth hormone treatment: a safety update from the KIGS database.
    Darendeliler F; Karagiannis G; Wilton P
    Horm Res; 2007; 68 Suppl 5():41-7. PubMed ID: 18174706
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term use of recombinant human growth hormone in children with chronic renal insufficiency.
    Yadin O; Fine RN
    Kidney Int Suppl; 1997 Mar; 58():S114-7. PubMed ID: 9067958
    [No Abstract]   [Full Text] [Related]  

  • 10. [Slipped capital femoral epiphysis and biosynthetic growth hormone therapy. A case report].
    Mazzarello L; Franchi L; Gastaldi R; Sénès FM; Asquasciati G; de Toni T
    Minerva Pediatr; 1994 Mar; 46(3):109-12. PubMed ID: 8035756
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Growth hormone therapy with norditropin ( somatropin ) in growth hormone deficiency.
    Pawlikowska-Haddal A
    Expert Opin Biol Ther; 2013 Jun; 13(6):927-32. PubMed ID: 23662811
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Orthopedic complications related to growth hormone therapy in a pediatric population.
    Haidar RK; Nasrallah MP; Der-Boghossian AH; Ghanem IB
    J Pediatr Orthop B; 2011 Jan; 20(1):57-61. PubMed ID: 20811297
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acromegaly induced by growth hormone replacement therapy.
    Karges B; Pfäffle R; Boehm BO; Karges W
    Horm Res; 2004; 61(4):165-9. PubMed ID: 14707471
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolic effects of 20-kilodalton human growth hormone (20K-hGH) for adults with growth hormone deficiency: results of an exploratory uncontrolled multicenter clinical trial of 20K-hGH.
    Hayakawa M; Shimazaki Y; Tsushima T; Kato Y; Takano K; Chihara K; Shimatsu A; Irie M
    J Clin Endocrinol Metab; 2004 Apr; 89(4):1562-71. PubMed ID: 15070913
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Counteracting the sigma. Lipodystrophy decreases prognosis and quality of life].
    MMW Fortschr Med; 2003 Apr; 145 Spec No 1():26-7. PubMed ID: 15011580
    [No Abstract]   [Full Text] [Related]  

  • 16. Final height in children with idiopathic growth hormone deficiency treated with a fixed dose of recombinant growth hormone.
    Rachmiel M; Rota V; Atenafu E; Daneman D; Hamilton J
    Horm Res; 2007; 68(5):236-43. PubMed ID: 17396034
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment with recombinant human growth hormone during childhood is associated with increased intraocular pressure.
    Youngster I; Rachmiel R; Pinhas-Hamiel O; Bistritzer T; Zuckerman-Levin N; de Vries L; Naugolny L; Eyal O; Braunstein R; Rachmiel M
    J Pediatr; 2012 Dec; 161(6):1116-9. PubMed ID: 22727870
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pegylated long-acting human growth hormone is well-tolerated in healthy subjects and possesses a potential once-weekly pharmacokinetic and pharmacodynamic treatment profile.
    Rasmussen MH; Bysted BV; Anderson TW; Klitgaard T; Madsen J
    J Clin Endocrinol Metab; 2010 Jul; 95(7):3411-7. PubMed ID: 20427496
    [TBL] [Abstract][Full Text] [Related]  

  • 19. POI: a score to modulate GH treatment in children with Prader-Willi syndrome.
    Salvatoni A; Berini J; Chiumello G; Crinò A; Di Candia S; Gargantini L; Grugni G; Iughetti L; Luce A; Musolino G; Sogno Valin P; Spica Russotto V; Trifirò G
    Horm Res Paediatr; 2012; 78(3):201-2. PubMed ID: 22986481
    [No Abstract]   [Full Text] [Related]  

  • 20. Is safety of childhood growth hormone therapy related to dose? Data from a large observational study.
    Sävendahl L; Pournara E; Pedersen BT; Blankenstein O
    Eur J Endocrinol; 2016 May; 174(5):681-91. PubMed ID: 26903552
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.